Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole-bismuth-metronidazole quadruple therapy with tetracycline versus amoxicillin for initial Helicobacter pylori eradication
ChiCTR1900024964Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esomeprazole, bismuth subsalicylate, metronidazole, tetracycline and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Eradication rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
esomeprazolebismuth subsalicylatemetronidazoletetracyclineamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR1900024964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024964.